nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MAPK7—Signalling to ERK5—MAP2K5—restless legs syndrome	0.112	0.244	CbGpPWpGaD
Crizotinib—ACVR1—pes—restless legs syndrome	0.0325	0.0601	CbGeAlD
Crizotinib—RPS6KB1—leg—restless legs syndrome	0.0134	0.0247	CbGeAlD
Crizotinib—BMPR1B—peripheral nervous system—restless legs syndrome	0.0133	0.0246	CbGeAlD
Crizotinib—RPS6KB1—hindlimb—restless legs syndrome	0.012	0.0221	CbGeAlD
Crizotinib—PRKD1—Cardiac Hypertrophic Response—MAP2K5—restless legs syndrome	0.0118	0.0257	CbGpPWpGaD
Crizotinib—MAPK7—Trk receptor signaling mediated by the MAPK pathway—MAP2K5—restless legs syndrome	0.0116	0.0253	CbGpPWpGaD
Crizotinib—ALK—Differentiation Pathway—TF—restless legs syndrome	0.0116	0.0252	CbGpPWpGaD
Crizotinib—MAP3K2—Trk receptor signaling mediated by the MAPK pathway—MAP2K5—restless legs syndrome	0.0106	0.0231	CbGpPWpGaD
Crizotinib—RPS6KB1—appendage—restless legs syndrome	0.0103	0.0189	CbGeAlD
Crizotinib—IKBKE—Cardiac Hypertrophic Response—MAP2K5—restless legs syndrome	0.00868	0.0189	CbGpPWpGaD
Crizotinib—MAP3K3—peripheral nervous system—restless legs syndrome	0.00844	0.0156	CbGeAlD
Crizotinib—TNK1—Focal Adhesion—MAP2K5—restless legs syndrome	0.00808	0.0176	CbGpPWpGaD
Crizotinib—MAPK7—Cardiac Hypertrophic Response—MAP2K5—restless legs syndrome	0.00789	0.0172	CbGpPWpGaD
Crizotinib—EPHA4—nerve—restless legs syndrome	0.00787	0.0145	CbGeAlD
Crizotinib—MET—Signaling Pathways in Glioblastoma—MAP2K5—restless legs syndrome	0.00741	0.0162	CbGpPWpGaD
Crizotinib—MAP4K1—Cardiac Hypertrophic Response—MAP2K5—restless legs syndrome	0.00719	0.0157	CbGpPWpGaD
Crizotinib—TAOK2—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00676	0.0148	CbGpPWpGaD
Crizotinib—MUSK—nervous system—restless legs syndrome	0.00658	0.0121	CbGeAlD
Crizotinib—IKBKE—MicroRNAs in cardiomyocyte hypertrophy—MAP2K5—restless legs syndrome	0.00618	0.0135	CbGpPWpGaD
Crizotinib—MAP4K2—Insulin Signaling—MAP2K5—restless legs syndrome	0.00598	0.013	CbGpPWpGaD
Crizotinib—ROS1—brain—restless legs syndrome	0.00591	0.0109	CbGeAlD
Crizotinib—IGF1R—Signaling Pathways in Glioblastoma—MAP2K5—restless legs syndrome	0.00586	0.0128	CbGpPWpGaD
Crizotinib—STK3—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00575	0.0125	CbGpPWpGaD
Crizotinib—IGF1R—MicroRNAs in cardiomyocyte hypertrophy—MAP2K5—restless legs syndrome	0.00575	0.0125	CbGpPWpGaD
Crizotinib—MAP4K5—Insulin Signaling—MAP2K5—restless legs syndrome	0.00573	0.0125	CbGpPWpGaD
Crizotinib—EPHB4—EPHB forward signaling—TF—restless legs syndrome	0.00567	0.0124	CbGpPWpGaD
Crizotinib—CASK—Syndecan-3-mediated signaling events—POMC—restless legs syndrome	0.00565	0.0123	CbGpPWpGaD
Crizotinib—MAPK7—MicroRNAs in cardiomyocyte hypertrophy—MAP2K5—restless legs syndrome	0.00562	0.0123	CbGpPWpGaD
Crizotinib—MET—brainstem—restless legs syndrome	0.00556	0.0103	CbGeAlD
Crizotinib—CDK7—Cardiac Hypertrophic Response—MAP2K5—restless legs syndrome	0.00545	0.0119	CbGpPWpGaD
Crizotinib—EPHA7—brain—restless legs syndrome	0.00541	0.00998	CbGeAlD
Crizotinib—ANKK1—nervous system—restless legs syndrome	0.00536	0.0099	CbGeAlD
Crizotinib—MAP3K12—Insulin Signaling—MAP2K5—restless legs syndrome	0.00533	0.0116	CbGpPWpGaD
Crizotinib—NTRK1—Circadian rythm related genes—BTBD9—restless legs syndrome	0.00514	0.0112	CbGpPWpGaD
Crizotinib—MAP3K12—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00512	0.0112	CbGpPWpGaD
Crizotinib—MAPK7—Integrin-mediated Cell Adhesion—MAP2K5—restless legs syndrome	0.00489	0.0107	CbGpPWpGaD
Crizotinib—ACVR1B—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00482	0.0105	CbGpPWpGaD
Crizotinib—MAPK7—ErbB1 downstream signaling—MAP2K5—restless legs syndrome	0.00471	0.0103	CbGpPWpGaD
Crizotinib—TNK2—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.0047	0.0103	CbGpPWpGaD
Crizotinib—TYRO3—brainstem—restless legs syndrome	0.00455	0.00839	CbGeAlD
Crizotinib—IGF1R—brainstem—restless legs syndrome	0.00437	0.00806	CbGeAlD
Crizotinib—MAP3K2—ErbB1 downstream signaling—MAP2K5—restless legs syndrome	0.00429	0.00936	CbGpPWpGaD
Crizotinib—CSF1R—Differentiation Pathway—TF—restless legs syndrome	0.00428	0.00934	CbGpPWpGaD
Crizotinib—TXK—Focal Adhesion—MAP2K5—restless legs syndrome	0.00425	0.00927	CbGpPWpGaD
Crizotinib—TNK2—Focal Adhesion—MAP2K5—restless legs syndrome	0.00414	0.00903	CbGpPWpGaD
Crizotinib—CDK7—MicroRNAs in cardiomyocyte hypertrophy—MAP2K5—restless legs syndrome	0.00388	0.00848	CbGpPWpGaD
Crizotinib—MAP3K12—brainstem—restless legs syndrome	0.00387	0.00713	CbGeAlD
Crizotinib—NEK9—nervous system—restless legs syndrome	0.00384	0.00709	CbGeAlD
Crizotinib—STK35—brainstem—restless legs syndrome	0.00379	0.00699	CbGeAlD
Crizotinib—MET—Focal Adhesion—MAP2K5—restless legs syndrome	0.00378	0.00826	CbGpPWpGaD
Crizotinib—NEK9—central nervous system—restless legs syndrome	0.0037	0.00683	CbGeAlD
Crizotinib—MAPK7—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.00365	0.00798	CbGpPWpGaD
Crizotinib—PRKD1—nervous system—restless legs syndrome	0.0035	0.00646	CbGeAlD
Crizotinib—SIK2—nervous system—restless legs syndrome	0.00346	0.00638	CbGeAlD
Crizotinib—IGF1R—Insulin Signaling—MAP2K5—restless legs syndrome	0.00343	0.00749	CbGpPWpGaD
Crizotinib—LIMK2—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.0034	0.00742	CbGpPWpGaD
Crizotinib—EPHA4—brainstem—restless legs syndrome	0.00338	0.00623	CbGeAlD
Crizotinib—PRKD1—central nervous system—restless legs syndrome	0.00337	0.00622	CbGeAlD
Crizotinib—MAPK7—Insulin Signaling—MAP2K5—restless legs syndrome	0.00336	0.00733	CbGpPWpGaD
Crizotinib—MAP3K2—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.00333	0.00727	CbGpPWpGaD
Crizotinib—SIK2—central nervous system—restless legs syndrome	0.00333	0.00614	CbGeAlD
Crizotinib—MAPK7—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00333	0.00726	CbGpPWpGaD
Crizotinib—MAPK7—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00323	0.00705	CbGpPWpGaD
Crizotinib—MAPK7—nervous system—restless legs syndrome	0.00311	0.00574	CbGeAlD
Crizotinib—AURKA—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00311	0.00679	CbGpPWpGaD
Crizotinib—EPHA8—nervous system—restless legs syndrome	0.00308	0.00568	CbGeAlD
Crizotinib—MAP3K2—Insulin Signaling—MAP2K5—restless legs syndrome	0.00306	0.00668	CbGpPWpGaD
Crizotinib—MAP4K1—Insulin Signaling—MAP2K5—restless legs syndrome	0.00306	0.00668	CbGpPWpGaD
Crizotinib—MAP3K2—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00303	0.00661	CbGpPWpGaD
Crizotinib—MAP4K1—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00303	0.00661	CbGpPWpGaD
Crizotinib—DCLK1—spinal cord—restless legs syndrome	0.00303	0.00559	CbGeAlD
Crizotinib—MAPK7—central nervous system—restless legs syndrome	0.003	0.00553	CbGeAlD
Crizotinib—IGF1R—Focal Adhesion—MAP2K5—restless legs syndrome	0.00299	0.00653	CbGpPWpGaD
Crizotinib—EPHA8—central nervous system—restless legs syndrome	0.00297	0.00547	CbGeAlD
Crizotinib—MAP3K2—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00294	0.00642	CbGpPWpGaD
Crizotinib—MAP4K1—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00294	0.00642	CbGpPWpGaD
Crizotinib—NEK9—brain—restless legs syndrome	0.00294	0.00542	CbGeAlD
Crizotinib—MAPK7—Focal Adhesion—MAP2K5—restless legs syndrome	0.00293	0.00639	CbGpPWpGaD
Crizotinib—MET—nervous system—restless legs syndrome	0.00291	0.00537	CbGeAlD
Crizotinib—PTK2—EPHB forward signaling—TF—restless legs syndrome	0.00287	0.00626	CbGpPWpGaD
Crizotinib—EPHA5—spinal cord—restless legs syndrome	0.00283	0.00522	CbGeAlD
Crizotinib—FER—spinal cord—restless legs syndrome	0.00283	0.00522	CbGeAlD
Crizotinib—TYRO3—spinal cord—restless legs syndrome	0.00283	0.00522	CbGeAlD
Crizotinib—CDK7—nervous system—restless legs syndrome	0.00282	0.0052	CbGeAlD
Crizotinib—MET—central nervous system—restless legs syndrome	0.0028	0.00517	CbGeAlD
Crizotinib—MAPK7—NGF signalling via TRKA from the plasma membrane—MAP2K5—restless legs syndrome	0.00274	0.00599	CbGpPWpGaD
Crizotinib—CDK7—central nervous system—restless legs syndrome	0.00271	0.005	CbGeAlD
Crizotinib—EPHA3—nervous system—restless legs syndrome	0.00269	0.00497	CbGeAlD
Crizotinib—ACVR1B—nervous system—restless legs syndrome	0.00269	0.00497	CbGeAlD
Crizotinib—PRKD1—brain—restless legs syndrome	0.00268	0.00494	CbGeAlD
Crizotinib—SIK2—brain—restless legs syndrome	0.00264	0.00487	CbGeAlD
Crizotinib—LIMK1—brain—restless legs syndrome	0.00264	0.00487	CbGeAlD
Crizotinib—MAP3K3—Insulin Signaling—MAP2K5—restless legs syndrome	0.00263	0.00574	CbGpPWpGaD
Crizotinib—MAP3K3—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.0026	0.00569	CbGpPWpGaD
Crizotinib—EPHA3—central nervous system—restless legs syndrome	0.00259	0.00478	CbGeAlD
Crizotinib—ACVR1B—central nervous system—restless legs syndrome	0.00259	0.00478	CbGeAlD
Crizotinib—TAOK3—brainstem—restless legs syndrome	0.00258	0.00475	CbGeAlD
Crizotinib—PRKD3—brain—restless legs syndrome	0.00257	0.00475	CbGeAlD
Crizotinib—EPHA6—nervous system—restless legs syndrome	0.00257	0.00474	CbGeAlD
Crizotinib—JAK3—nervous system—restless legs syndrome	0.00257	0.00474	CbGeAlD
Crizotinib—TESK1—spinal cord—restless legs syndrome	0.00255	0.00471	CbGeAlD
Crizotinib—DCLK1—nervous system—restless legs syndrome	0.00255	0.00471	CbGeAlD
Crizotinib—PTK2—Integrin-mediated Cell Adhesion—MAP2K5—restless legs syndrome	0.00253	0.00552	CbGpPWpGaD
Crizotinib—STK4—nervous system—restless legs syndrome	0.00252	0.00465	CbGeAlD
Crizotinib—DSTYK—brain—restless legs syndrome	0.00251	0.00464	CbGeAlD
Crizotinib—EPHA6—central nervous system—restless legs syndrome	0.00247	0.00456	CbGeAlD
Crizotinib—JAK3—central nervous system—restless legs syndrome	0.00247	0.00456	CbGeAlD
Crizotinib—DCLK1—central nervous system—restless legs syndrome	0.00246	0.00453	CbGeAlD
Crizotinib—LTK—brain—restless legs syndrome	0.00246	0.00453	CbGeAlD
Crizotinib—CASK—brain—restless legs syndrome	0.00246	0.00453	CbGeAlD
Crizotinib—LIMK2—spinal cord—restless legs syndrome	0.00243	0.00448	CbGeAlD
Crizotinib—STK4—central nervous system—restless legs syndrome	0.00243	0.00448	CbGeAlD
Crizotinib—MAP3K12—spinal cord—restless legs syndrome	0.0024	0.00444	CbGeAlD
Crizotinib—ACVR1—spinal cord—restless legs syndrome	0.0024	0.00444	CbGeAlD
Crizotinib—FER—nervous system—restless legs syndrome	0.00238	0.0044	CbGeAlD
Crizotinib—EPHA5—nervous system—restless legs syndrome	0.00238	0.0044	CbGeAlD
Crizotinib—ALK—nervous system—restless legs syndrome	0.00238	0.0044	CbGeAlD
Crizotinib—TYRO3—nervous system—restless legs syndrome	0.00238	0.0044	CbGeAlD
Crizotinib—MAPK7—brain—restless legs syndrome	0.00238	0.00439	CbGeAlD
Crizotinib—PTK2B—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.00237	0.00518	CbGpPWpGaD
Crizotinib—LYN—nervous system—restless legs syndrome	0.00237	0.00437	CbGeAlD
Crizotinib—EPHA8—brain—restless legs syndrome	0.00235	0.00434	CbGeAlD
Crizotinib—FES—brain—restless legs syndrome	0.00235	0.00434	CbGeAlD
Crizotinib—MAP3K19—nervous system—restless legs syndrome	0.00233	0.00431	CbGeAlD
Crizotinib—BMPR1B—nervous system—restless legs syndrome	0.00233	0.00431	CbGeAlD
Crizotinib—TYRO3—central nervous system—restless legs syndrome	0.00229	0.00423	CbGeAlD
Crizotinib—FER—central nervous system—restless legs syndrome	0.00229	0.00423	CbGeAlD
Crizotinib—ALK—central nervous system—restless legs syndrome	0.00229	0.00423	CbGeAlD
Crizotinib—EPHA5—central nervous system—restless legs syndrome	0.00229	0.00423	CbGeAlD
Crizotinib—TNK2—nervous system—restless legs syndrome	0.00229	0.00422	CbGeAlD
Crizotinib—IGF1R—nervous system—restless legs syndrome	0.00229	0.00422	CbGeAlD
Crizotinib—LYN—central nervous system—restless legs syndrome	0.00228	0.00421	CbGeAlD
Crizotinib—NTRK1—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.00227	0.00496	CbGpPWpGaD
Crizotinib—BMP2K—spinal cord—restless legs syndrome	0.00227	0.00418	CbGeAlD
Crizotinib—BMPR1B—central nervous system—restless legs syndrome	0.00225	0.00415	CbGeAlD
Crizotinib—MAP3K19—central nervous system—restless legs syndrome	0.00225	0.00415	CbGeAlD
Crizotinib—TIE1—nervous system—restless legs syndrome	0.00223	0.00411	CbGeAlD
Crizotinib—MET—brain—restless legs syndrome	0.00223	0.00411	CbGeAlD
Crizotinib—IGF1R—central nervous system—restless legs syndrome	0.0022	0.00407	CbGeAlD
Crizotinib—TNK2—central nervous system—restless legs syndrome	0.0022	0.00407	CbGeAlD
Crizotinib—RPS6KB1—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.0022	0.00481	CbGpPWpGaD
Crizotinib—RIPK2—spinal cord—restless legs syndrome	0.00217	0.00401	CbGeAlD
Crizotinib—AURKA—nervous system—restless legs syndrome	0.00217	0.004	CbGeAlD
Crizotinib—PTK2B—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00216	0.00471	CbGpPWpGaD
Crizotinib—CDK7—brain—restless legs syndrome	0.00215	0.00397	CbGeAlD
Crizotinib—TESK1—nervous system—restless legs syndrome	0.00215	0.00397	CbGeAlD
Crizotinib—TIE1—central nervous system—restless legs syndrome	0.00214	0.00396	CbGeAlD
Crizotinib—TAOK2—brain—restless legs syndrome	0.00214	0.00394	CbGeAlD
Crizotinib—MAPK7—Signaling by NGF—MAP2K5—restless legs syndrome	0.00211	0.00461	CbGpPWpGaD
Crizotinib—MERTK—nervous system—restless legs syndrome	0.00209	0.00386	CbGeAlD
Crizotinib—AURKA—central nervous system—restless legs syndrome	0.00209	0.00386	CbGeAlD
Crizotinib—TESK1—central nervous system—restless legs syndrome	0.00207	0.00382	CbGeAlD
Crizotinib—ACVR1B—brain—restless legs syndrome	0.00206	0.0038	CbGeAlD
Crizotinib—EPHA3—brain—restless legs syndrome	0.00206	0.0038	CbGeAlD
Crizotinib—LIMK2—nervous system—restless legs syndrome	0.00205	0.00378	CbGeAlD
Crizotinib—ACVR1—nervous system—restless legs syndrome	0.00203	0.00374	CbGeAlD
Crizotinib—MAP3K12—nervous system—restless legs syndrome	0.00203	0.00374	CbGeAlD
Crizotinib—RPS6KB1—Insulin Signaling—MAP2K5—restless legs syndrome	0.00202	0.00442	CbGpPWpGaD
Crizotinib—PTK2—spinal cord—restless legs syndrome	0.00202	0.00372	CbGeAlD
Crizotinib—TBK1—spinal cord—restless legs syndrome	0.00202	0.00372	CbGeAlD
Crizotinib—MERTK—central nervous system—restless legs syndrome	0.00202	0.00372	CbGeAlD
Crizotinib—NTRK1—MAPK Signaling Pathway—MAP2K5—restless legs syndrome	0.00201	0.00438	CbGpPWpGaD
Crizotinib—RPS6KB1—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.002	0.00437	CbGpPWpGaD
Crizotinib—TYK2—spinal cord—restless legs syndrome	0.002	0.0037	CbGeAlD
Crizotinib—STK35—nervous system—restless legs syndrome	0.00198	0.00366	CbGeAlD
Crizotinib—LIMK2—central nervous system—restless legs syndrome	0.00197	0.00364	CbGeAlD
Crizotinib—EPHA6—brain—restless legs syndrome	0.00196	0.00362	CbGeAlD
Crizotinib—JAK3—brain—restless legs syndrome	0.00196	0.00362	CbGeAlD
Crizotinib—DCLK1—brain—restless legs syndrome	0.00195	0.0036	CbGeAlD
Crizotinib—ACVR1—central nervous system—restless legs syndrome	0.00195	0.0036	CbGeAlD
Crizotinib—MAP3K12—central nervous system—restless legs syndrome	0.00195	0.0036	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—restless legs syndrome	0.00194	0.00358	CbGeAlD
Crizotinib—PLK4—brain—restless legs syndrome	0.00194	0.00358	CbGeAlD
Crizotinib—STK4—brain—restless legs syndrome	0.00193	0.00356	CbGeAlD
Crizotinib—AXL—spinal cord—restless legs syndrome	0.00192	0.00354	CbGeAlD
Crizotinib—STK35—central nervous system—restless legs syndrome	0.00191	0.00353	CbGeAlD
Crizotinib—BMP2K—nervous system—restless legs syndrome	0.00191	0.00353	CbGeAlD
Crizotinib—BLK—Focal Adhesion—MAP2K5—restless legs syndrome	0.00185	0.00405	CbGpPWpGaD
Crizotinib—SLK—spinal cord—restless legs syndrome	0.00185	0.00341	CbGeAlD
Crizotinib—FGR—Focal Adhesion—MAP2K5—restless legs syndrome	0.00185	0.00404	CbGpPWpGaD
Crizotinib—PTK2B—nervous system—restless legs syndrome	0.00185	0.0034	CbGeAlD
Crizotinib—BMP2K—central nervous system—restless legs syndrome	0.00184	0.00339	CbGeAlD
Crizotinib—EPHB4—spinal cord—restless legs syndrome	0.00184	0.00339	CbGeAlD
Crizotinib—JAK2—spinal cord—restless legs syndrome	0.00182	0.00336	CbGeAlD
Crizotinib—EPHA5—brain—restless legs syndrome	0.00182	0.00336	CbGeAlD
Crizotinib—ALK—brain—restless legs syndrome	0.00182	0.00336	CbGeAlD
Crizotinib—FER—brain—restless legs syndrome	0.00182	0.00336	CbGeAlD
Crizotinib—TYRO3—brain—restless legs syndrome	0.00182	0.00336	CbGeAlD
Crizotinib—LYN—brain—restless legs syndrome	0.00181	0.00334	CbGeAlD
Crizotinib—TNK1—brain—restless legs syndrome	0.0018	0.00333	CbGeAlD
Crizotinib—BMPR1B—brain—restless legs syndrome	0.00178	0.00329	CbGeAlD
Crizotinib—MAP3K19—brain—restless legs syndrome	0.00178	0.00329	CbGeAlD
Crizotinib—MAP4K1—brain—restless legs syndrome	0.00178	0.00329	CbGeAlD
Crizotinib—ABL1—brainstem—restless legs syndrome	0.00178	0.00329	CbGeAlD
Crizotinib—PTK2B—central nervous system—restless legs syndrome	0.00178	0.00328	CbGeAlD
Crizotinib—EPHA4—nervous system—restless legs syndrome	0.00177	0.00326	CbGeAlD
Crizotinib—TEK—spinal cord—restless legs syndrome	0.00176	0.00324	CbGeAlD
Crizotinib—MAP4K5—spinal cord—restless legs syndrome	0.00176	0.00324	CbGeAlD
Crizotinib—MAP3K3—spinal cord—restless legs syndrome	0.00176	0.00324	CbGeAlD
Crizotinib—TNK2—brain—restless legs syndrome	0.00175	0.00323	CbGeAlD
Crizotinib—IGF1R—brain—restless legs syndrome	0.00175	0.00323	CbGeAlD
Crizotinib—MAP3K2—nervous system—restless legs syndrome	0.00173	0.0032	CbGeAlD
Crizotinib—MAP4K2—brain—restless legs syndrome	0.00173	0.00318	CbGeAlD
Crizotinib—PTK2—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00172	0.00375	CbGpPWpGaD
Crizotinib—NTRK1—NGF signalling via TRKA from the plasma membrane—MAP2K5—restless legs syndrome	0.0017	0.00372	CbGpPWpGaD
Crizotinib—EPHA4—central nervous system—restless legs syndrome	0.0017	0.00314	CbGeAlD
Crizotinib—TIE1—brain—restless legs syndrome	0.0017	0.00314	CbGeAlD
Crizotinib—STK3—brain—restless legs syndrome	0.0017	0.00314	CbGeAlD
Crizotinib—PTK2—nervous system—restless legs syndrome	0.0017	0.00313	CbGeAlD
Crizotinib—TBK1—nervous system—restless legs syndrome	0.0017	0.00313	CbGeAlD
Crizotinib—TYK2—nervous system—restless legs syndrome	0.00169	0.00311	CbGeAlD
Crizotinib—EPHB6—spinal cord—restless legs syndrome	0.00168	0.0031	CbGeAlD
Crizotinib—MAP3K2—central nervous system—restless legs syndrome	0.00167	0.00308	CbGeAlD
Crizotinib—AURKA—brain—restless legs syndrome	0.00166	0.00306	CbGeAlD
Crizotinib—TESK1—brain—restless legs syndrome	0.00165	0.00304	CbGeAlD
Crizotinib—PTK2—central nervous system—restless legs syndrome	0.00164	0.00302	CbGeAlD
Crizotinib—TBK1—central nervous system—restless legs syndrome	0.00164	0.00302	CbGeAlD
Crizotinib—RPS6KB1—nervous system—restless legs syndrome	0.00163	0.00302	CbGeAlD
Crizotinib—TYK2—central nervous system—restless legs syndrome	0.00162	0.003	CbGeAlD
Crizotinib—FGR—nervous system—restless legs syndrome	0.00162	0.003	CbGeAlD
Crizotinib—YES1—spinal cord—restless legs syndrome	0.00162	0.00299	CbGeAlD
Crizotinib—AXL—nervous system—restless legs syndrome	0.00162	0.00299	CbGeAlD
Crizotinib—TAOK3—spinal cord—restless legs syndrome	0.0016	0.00295	CbGeAlD
Crizotinib—MERTK—brain—restless legs syndrome	0.0016	0.00295	CbGeAlD
Crizotinib—SRC—Signaling Pathways in Glioblastoma—MAP2K5—restless legs syndrome	0.00158	0.00345	CbGpPWpGaD
Crizotinib—RPS6KB1—central nervous system—restless legs syndrome	0.00157	0.0029	CbGeAlD
Crizotinib—LIMK2—brain—restless legs syndrome	0.00157	0.00289	CbGeAlD
Crizotinib—FGR—central nervous system—restless legs syndrome	0.00156	0.00289	CbGeAlD
Crizotinib—SRC—spinal cord—restless legs syndrome	0.00156	0.00288	CbGeAlD
Crizotinib—NUAK2—brain—restless legs syndrome	0.00156	0.00288	CbGeAlD
Crizotinib—AXL—central nervous system—restless legs syndrome	0.00156	0.00287	CbGeAlD
Crizotinib—MAP3K12—brain—restless legs syndrome	0.00155	0.00286	CbGeAlD
Crizotinib—ACVR1—brain—restless legs syndrome	0.00155	0.00286	CbGeAlD
Crizotinib—JAK2—nervous system—restless legs syndrome	0.00154	0.00283	CbGeAlD
Crizotinib—SRC—EPHB forward signaling—TF—restless legs syndrome	0.00153	0.00334	CbGpPWpGaD
Crizotinib—STK35—brain—restless legs syndrome	0.00152	0.0028	CbGeAlD
Crizotinib—EPHA2—nervous system—restless legs syndrome	0.00152	0.0028	CbGeAlD
Crizotinib—PTK2—Focal Adhesion—MAP2K5—restless legs syndrome	0.00151	0.0033	CbGpPWpGaD
Crizotinib—MERTK—Hemostasis—TF—restless legs syndrome	0.00149	0.00326	CbGpPWpGaD
Crizotinib—MAP4K5—nervous system—restless legs syndrome	0.00148	0.00273	CbGeAlD
Crizotinib—TEK—nervous system—restless legs syndrome	0.00148	0.00273	CbGeAlD
Crizotinib—MAP3K3—nervous system—restless legs syndrome	0.00148	0.00273	CbGeAlD
Crizotinib—ABL2—brain—restless legs syndrome	0.00148	0.00273	CbGeAlD
Crizotinib—JAK2—central nervous system—restless legs syndrome	0.00148	0.00273	CbGeAlD
Crizotinib—EPHA2—central nervous system—restless legs syndrome	0.00146	0.00269	CbGeAlD
Crizotinib—BMP2K—brain—restless legs syndrome	0.00146	0.00269	CbGeAlD
Crizotinib—TEK—central nervous system—restless legs syndrome	0.00142	0.00263	CbGeAlD
Crizotinib—MAP3K3—central nervous system—restless legs syndrome	0.00142	0.00263	CbGeAlD
Crizotinib—MAP4K5—central nervous system—restless legs syndrome	0.00142	0.00263	CbGeAlD
Crizotinib—EPHB6—nervous system—restless legs syndrome	0.00141	0.00261	CbGeAlD
Crizotinib—PTK2B—brain—restless legs syndrome	0.00141	0.0026	CbGeAlD
Crizotinib—CSF1R—spinal cord—restless legs syndrome	0.0014	0.00258	CbGeAlD
Crizotinib—RIPK2—brain—restless legs syndrome	0.0014	0.00258	CbGeAlD
Crizotinib—RIPK2—Signaling by NGF—MAP2K5—restless legs syndrome	0.00139	0.00303	CbGpPWpGaD
Crizotinib—YES1—nervous system—restless legs syndrome	0.00137	0.00252	CbGeAlD
Crizotinib—EPHB6—central nervous system—restless legs syndrome	0.00136	0.00251	CbGeAlD
Crizotinib—STK10—nervous system—restless legs syndrome	0.00135	0.0025	CbGeAlD
Crizotinib—EPHA4—brain—restless legs syndrome	0.00135	0.00249	CbGeAlD
Crizotinib—TAOK3—nervous system—restless legs syndrome	0.00135	0.00249	CbGeAlD
Crizotinib—SRC—Integrin-mediated Cell Adhesion—MAP2K5—restless legs syndrome	0.00135	0.00295	CbGpPWpGaD
Crizotinib—MAP3K2—brain—restless legs syndrome	0.00133	0.00245	CbGeAlD
Crizotinib—YES1—central nervous system—restless legs syndrome	0.00132	0.00243	CbGeAlD
Crizotinib—SRC—nervous system—restless legs syndrome	0.00131	0.00243	CbGeAlD
Crizotinib—NTRK1—Signaling by NGF—MAP2K5—restless legs syndrome	0.00131	0.00286	CbGpPWpGaD
Crizotinib—STK10—central nervous system—restless legs syndrome	0.0013	0.00241	CbGeAlD
Crizotinib—JAK2—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.0013	0.00284	CbGpPWpGaD
Crizotinib—TAOK3—central nervous system—restless legs syndrome	0.0013	0.0024	CbGeAlD
Crizotinib—PTK2—brain—restless legs syndrome	0.0013	0.0024	CbGeAlD
Crizotinib—TBK1—brain—restless legs syndrome	0.0013	0.0024	CbGeAlD
Crizotinib—SRC—ErbB1 downstream signaling—MAP2K5—restless legs syndrome	0.0013	0.00283	CbGpPWpGaD
Crizotinib—TYK2—brain—restless legs syndrome	0.00129	0.00238	CbGeAlD
Crizotinib—TYK2—NGF signalling via TRKA from the plasma membrane—MAP2K5—restless legs syndrome	0.00129	0.00281	CbGpPWpGaD
Crizotinib—IRAK1—brain—restless legs syndrome	0.00127	0.00235	CbGeAlD
Crizotinib—SRC—central nervous system—restless legs syndrome	0.00127	0.00234	CbGeAlD
Crizotinib—ABL1—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00126	0.00275	CbGpPWpGaD
Crizotinib—RPS6KB1—brain—restless legs syndrome	0.00125	0.00231	CbGeAlD
Crizotinib—FGR—brain—restless legs syndrome	0.00124	0.00229	CbGeAlD
Crizotinib—AXL—brain—restless legs syndrome	0.00124	0.00228	CbGeAlD
Crizotinib—SLK—brain—restless legs syndrome	0.00119	0.0022	CbGeAlD
Crizotinib—JAK2—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.00118	0.00258	CbGpPWpGaD
Crizotinib—EPHB4—brain—restless legs syndrome	0.00118	0.00218	CbGeAlD
Crizotinib—CSF1R—nervous system—restless legs syndrome	0.00118	0.00218	CbGeAlD
Crizotinib—JAK2—brain—restless legs syndrome	0.00117	0.00217	CbGeAlD
Crizotinib—EPHA2—brain—restless legs syndrome	0.00116	0.00214	CbGeAlD
Crizotinib—SRC—Syndecan-3-mediated signaling events—POMC—restless legs syndrome	0.00116	0.00252	CbGpPWpGaD
Crizotinib—CSF1R—central nervous system—restless legs syndrome	0.00114	0.0021	CbGeAlD
Crizotinib—MAP4K5—brain—restless legs syndrome	0.00113	0.00209	CbGeAlD
Crizotinib—TEK—brain—restless legs syndrome	0.00113	0.00209	CbGeAlD
Crizotinib—MAP3K3—brain—restless legs syndrome	0.00113	0.00209	CbGeAlD
Crizotinib—ABL1—spinal cord—restless legs syndrome	0.00111	0.00204	CbGeAlD
Crizotinib—EPHB6—brain—restless legs syndrome	0.00108	0.00199	CbGeAlD
Crizotinib—YES1—brain—restless legs syndrome	0.00104	0.00193	CbGeAlD
Crizotinib—STK10—brain—restless legs syndrome	0.00104	0.00191	CbGeAlD
Crizotinib—TAOK3—brain—restless legs syndrome	0.00103	0.0019	CbGeAlD
Crizotinib—JAK3—Platelet activation, signaling and aggregation—TF—restless legs syndrome	0.00102	0.00223	CbGpPWpGaD
Crizotinib—IRAK1—Signaling by NGF—MAP2K5—restless legs syndrome	0.00102	0.00223	CbGpPWpGaD
Crizotinib—SRC—BDNF signaling pathway—MAP2K5—restless legs syndrome	0.00101	0.0022	CbGpPWpGaD
Crizotinib—SRC—brain—restless legs syndrome	0.001	0.00185	CbGeAlD
Crizotinib—TYK2—Signaling by NGF—MAP2K5—restless legs syndrome	0.00099	0.00216	CbGpPWpGaD
Crizotinib—JAK2—NGF signalling via TRKA from the plasma membrane—MAP2K5—restless legs syndrome	0.000976	0.00213	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—MAP2K5—restless legs syndrome	0.000949	0.00207	CbGpPWpGaD
Crizotinib—ABL1—nervous system—restless legs syndrome	0.000933	0.00172	CbGeAlD
Crizotinib—SRC—EGF/EGFR Signaling Pathway—MAP2K5—restless legs syndrome	0.000917	0.002	CbGpPWpGaD
Crizotinib—CSF1R—brain—restless legs syndrome	0.000902	0.00166	CbGeAlD
Crizotinib—ABL1—central nervous system—restless legs syndrome	0.000898	0.00166	CbGeAlD
Crizotinib—LCK—NGF signalling via TRKA from the plasma membrane—MAP2K5—restless legs syndrome	0.000855	0.00187	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—MAP2K5—restless legs syndrome	0.000807	0.00176	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—MAP2K5—restless legs syndrome	0.000807	0.00176	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—MAP2K5—restless legs syndrome	0.000757	0.00165	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—MAP2K5—restless legs syndrome	0.000751	0.00164	CbGpPWpGaD
Crizotinib—PTK2—Platelet activation, signaling and aggregation—TF—restless legs syndrome	0.000716	0.00156	CbGpPWpGaD
Crizotinib—ABL1—brain—restless legs syndrome	0.000713	0.00132	CbGeAlD
Crizotinib—TEK—Hemostasis—TF—restless legs syndrome	0.0007	0.00153	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—MAP2K5—restless legs syndrome	0.000676	0.00148	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—MAP2K5—restless legs syndrome	0.000676	0.00148	CbGpPWpGaD
Crizotinib—PTK2—Corticotropin-releasing hormone—POMC—restless legs syndrome	0.000665	0.00145	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—MAP2K5—restless legs syndrome	0.000657	0.00144	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—MAP2K5—restless legs syndrome	0.000641	0.0014	CbGpPWpGaD
Crizotinib—ABCB1—HIF-1-alpha transcription factor network—TF—restless legs syndrome	0.000594	0.0013	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—MAP2K5—restless legs syndrome	0.000586	0.00128	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—MAP2K5—restless legs syndrome	0.000582	0.00127	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—TF—restless legs syndrome	0.000528	0.00115	CbGpPWpGaD
Crizotinib—LYN—Platelet activation, signaling and aggregation—TF—restless legs syndrome	0.000526	0.00115	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MAP2K5—restless legs syndrome	0.000512	0.00112	CbGpPWpGaD
Crizotinib—JAK2—Platelet activation, signaling and aggregation—TF—restless legs syndrome	0.000493	0.00108	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MAP2K5—restless legs syndrome	0.000463	0.00101	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MAP2K5—restless legs syndrome	0.000453	0.00099	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—TF—restless legs syndrome	0.000451	0.000984	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism of lipids and lipoproteins—POMC—restless legs syndrome	0.000446	0.000975	CbGpPWpGaD
Crizotinib—LCK—Platelet activation, signaling and aggregation—TF—restless legs syndrome	0.000431	0.000942	CbGpPWpGaD
Crizotinib—CYP3A4—nervous system—restless legs syndrome	0.00041	0.000756	CbGeAlD
Crizotinib—CYP3A4—central nervous system—restless legs syndrome	0.000395	0.000728	CbGeAlD
Crizotinib—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—restless legs syndrome	0.000391	0.000855	CbGpPWpGaD
Crizotinib—SRC—Platelet activation, signaling and aggregation—TF—restless legs syndrome	0.000382	0.000834	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TF—restless legs syndrome	0.000369	0.000805	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TF—restless legs syndrome	0.000364	0.000794	CbGpPWpGaD
Crizotinib—ABCB1—spinal cord—restless legs syndrome	0.000344	0.000635	CbGeAlD
Crizotinib—JAK3—Signaling Pathways—MAP2K5—restless legs syndrome	0.000335	0.000731	CbGpPWpGaD
Crizotinib—CYP3A5—Phase 1 - Functionalization of compounds—POMC—restless legs syndrome	0.000317	0.000693	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MAP2K5—restless legs syndrome	0.000299	0.000652	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MAP2K5—restless legs syndrome	0.000294	0.000642	CbGpPWpGaD
Crizotinib—ABCB1—nervous system—restless legs syndrome	0.00029	0.000535	CbGeAlD
Crizotinib—NTRK1—Signaling Pathways—MAP2K5—restless legs syndrome	0.000282	0.000615	CbGpPWpGaD
Crizotinib—ABCB1—central nervous system—restless legs syndrome	0.000279	0.000515	CbGeAlD
Crizotinib—RPS6KB1—Signaling Pathways—MAP2K5—restless legs syndrome	0.000273	0.000596	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—FXYD1—restless legs syndrome	0.000272	0.000595	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TF—restless legs syndrome	0.000271	0.000592	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TF—restless legs syndrome	0.00027	0.00059	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TF—restless legs syndrome	0.000254	0.000554	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAP2K5—restless legs syndrome	0.000234	0.000511	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—POMC—restless legs syndrome	0.000233	0.000509	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAP2K5—restless legs syndrome	0.000231	0.000504	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TF—restless legs syndrome	0.000222	0.000486	CbGpPWpGaD
Crizotinib—ABCB1—brain—restless legs syndrome	0.000222	0.000409	CbGeAlD
Crizotinib—IRAK1—Signaling Pathways—MAP2K5—restless legs syndrome	0.000219	0.000478	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAP2K5—restless legs syndrome	0.000213	0.000464	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—POMC—restless legs syndrome	0.000199	0.000434	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—POMC—restless legs syndrome	0.000198	0.000433	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TF—restless legs syndrome	0.000197	0.00043	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—POMC—restless legs syndrome	0.000189	0.000412	CbGpPWpGaD
Crizotinib—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—restless legs syndrome	0.000182	0.000397	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAP2K5—restless legs syndrome	0.000172	0.000376	CbGpPWpGaD
Crizotinib—CYP3A5—Biological oxidations—POMC—restless legs syndrome	0.000169	0.000368	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—POMC—restless legs syndrome	0.000166	0.000363	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—POMC—restless legs syndrome	0.000166	0.000363	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAP2K5—restless legs syndrome	0.000161	0.000352	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—POMC—restless legs syndrome	0.000158	0.000344	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—POMC—restless legs syndrome	0.000154	0.000335	CbGpPWpGaD
Crizotinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—restless legs syndrome	0.000148	0.000322	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—POMC—restless legs syndrome	0.000144	0.000315	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAP2K5—restless legs syndrome	0.000141	0.000308	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—POMC—restless legs syndrome	0.000139	0.000304	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—POMC—restless legs syndrome	0.000126	0.000275	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAP2K5—restless legs syndrome	0.000125	0.000273	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—POMC—restless legs syndrome	0.000114	0.000249	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—POMC—restless legs syndrome	0.000112	0.000243	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—TF—restless legs syndrome	0.000101	0.00022	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—POMC—restless legs syndrome	8.86e-05	0.000193	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—POMC—restless legs syndrome	8.24e-05	0.00018	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—POMC—restless legs syndrome	7.84e-05	0.000171	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—POMC—restless legs syndrome	7.39e-05	0.000161	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—POMC—restless legs syndrome	7.34e-05	0.00016	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—POMC—restless legs syndrome	7.24e-05	0.000158	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—POMC—restless legs syndrome	6.93e-05	0.000151	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—POMC—restless legs syndrome	6.72e-05	0.000147	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—POMC—restless legs syndrome	6.71e-05	0.000147	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—POMC—restless legs syndrome	5.76e-05	0.000126	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—POMC—restless legs syndrome	5.68e-05	0.000124	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—restless legs syndrome	5.39e-05	0.000118	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—restless legs syndrome	5.23e-05	0.000114	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—restless legs syndrome	4.24e-05	9.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—restless legs syndrome	3.96e-05	8.66e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—restless legs syndrome	3.47e-05	7.58e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—restless legs syndrome	3.07e-05	6.71e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—restless legs syndrome	2.88e-05	6.29e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—restless legs syndrome	2.18e-05	4.75e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—restless legs syndrome	1.34e-05	2.93e-05	CbGpPWpGaD
